Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “BIOMARIN PHARMACEUTICAL INC.”

112 pharma patents match "BIOMARIN PHARMACEUTICAL INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 112
Index total 30,257
Page 2 / 5

Quick answer

This filtered view shows 112 pharmaceutical patents matching "BIOMARIN PHARMACEUTICAL INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

112 results for “BIOMARIN PHARMACEUTICAL INC.” · 30,257 patents in full index Clear search

  1. US 10758598

    TPP-1 formulations and methods for treating CLN2 disease

    BIOMARIN PHARMACEUTICAL INC. · Granted Sep 1, 2020 · Expires Aug 27, 2040

    granted
  2. US 10683530

    Detection of oligosaccharides

    BIOMARIN PHARMACEUTICAL INC. · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted
  3. US 10646550

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    BIOMARIN PHARMACEUTICAL INC. · Granted May 12, 2020 · Expires May 7, 2040

    granted
  4. US 10563183

    Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted
  5. US 10526346

    Histone deacetylase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  6. US 10512675

    Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same

    BIOMARIN PHARMACEUTICAL INC. · Granted Dec 24, 2019 · Expires Dec 19, 2039

    granted
  7. US 10463718

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  8. US 10428028

    HDAC inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  9. US 10308608

    Histone deacetylase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Jun 4, 2019 · Expires May 30, 2039

    granted
  10. US 10301323

    Histone deacetylase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted May 28, 2019 · Expires May 23, 2039

    granted
  11. US 10300113

    Targeted therapeutic proteins

    BIOMARIN PHARMACEUTICAL INC. · Granted May 28, 2019 · Expires May 23, 2039

    granted
  12. US 10301369

    Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteins

    BIOMARIN PHARMACEUTICAL INC. · Granted May 28, 2019 · Expires May 23, 2039

    granted
  13. US 10279015

    TPP-1 formulations and methods for treating CLN2 disease

    BIOMARIN PHARMACEUTICAL INC. · Granted May 7, 2019 · Expires May 2, 2039

    granted
  14. US 10239832

    N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted
  15. US 10227323

    Glucosylceramide synthase inhibitors for the treatment of diseases

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted
  16. US 10227312

    Glucosylceramide synthase inhibitors for the treatment of diseases

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted
  17. US 10221408

    Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted
  18. US 10029988

    HDAC inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Jul 24, 2018 · Expires Jul 19, 2038

    granted
  19. US 9993481

    Methods and compositions for the treatment of metabolic disorders

    BIOMARIN PHARMACEUTICAL INC. · Granted Jun 12, 2018 · Expires Jun 7, 2038

    granted
  20. US 9908899

    Histone deacetylase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 6, 2018 · Expires Mar 1, 2038

    granted
  21. US 9907834

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    BIOMARIN PHARMACEUTICAL INC. · Granted Mar 6, 2018 · Expires Mar 1, 2038

    granted
  22. US 9873867

    Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Jan 23, 2018 · Expires Jan 18, 2038

    granted
  23. US 9845346

    Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Dec 19, 2017 · Expires Dec 14, 2037

    granted
  24. US 9834587

    Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Dec 5, 2017 · Expires Nov 30, 2037

    granted